Roswell Park Cancer Institute (RPCI) is an independent, free-standing research, education and clinical cancer care Institute. Dr. Donald Trump, CCSG PI and RPCI President/CEO, is responsible solely to the RPCI Board of Directors. RPCI has been continuously recognized as a Cancer Center since NCI first designated centers in 1974 and has been designated as a comprehensive center since that term was first employed. This application requests continued NCI support for another five years. RPCI occupies a 27 acre campus near downtown Buffalo. The RPCI campus consists of 1.6 million square feet (sf) of laboratory, office, clinical and education. An additional 142,000 sf clinical care, clinical research and office building began construction on April 18, 2013. New developments on the main campus since last review have included opening of the Centers for Immunotherapy, Robotic Surgery, and Personalized Medicine. An additional 16,000 sf of clinical space have been opened at three affiliate sites. While the population of the RPCI catchment area (the 8 county region of WNY from which ~86% of RPCI patients are drawn) has been generally stable at ~1.5M, the number of tumor registry cases has increased 25% since 2008. In 2012 RPCI physicians cared for 4,242 new tumor registry cases and a total of 8,626 new analytic and non-analytic cases. Since the last competitive renewal in 2008, RPCI has continued scientific, clinical, population science and education program growth, despite a difficult economic environment. This growth is demonstrated by: 1) recruitment of 137 new faculty clinicians and researchers, of which 51 are new CCSG members;2) a 17% increase in total peer-reviewed funding from 2008 to 2013;3) an increase in high-impact (impact factor>10) publications (91 to 193);4) increased accrual to first-in-human, phase I, investigator-initiated studies;24 accruals in 2008 vs 118 in 2012 and the highest phase I trial institutional recruitment in RPCI history;5) 2.5X increase in the number of therapeutic (treatment) trials supported by peer-reviewed funding (27 to 67);and 6) opening of three new satellite RPCI facilities. RPCI has expanded its educational programs, including an international program for the training of cancer scientists, clinicians and administrators from around the world. RPCI has successfully recruited three Senior Leaders, and invested $277 million in resources for the future to build on RPCI's unique opportunities in experimental therapeutics, translational medicine, genomics and education.

Public Health Relevance

Roswell Park Cancer Institute is a multidisciplinary, translational Comprehensive Cancer Center, with a mission to understand, prevent and cure cancer. RPCI utilizes CCSG support to build on unique strengths and opportunities, moving laboratory science into advanced treatment, prevention, diagnosis, and education.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016056-37S2
Application #
8884097
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$50,000
Indirect Cost
$20,554
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Goossens, Maria E; Isa, Fatima; Brinkman, Maree et al. (2016) International pooled study on diet and bladder cancer: the bladder cancer, epidemiology and nutritional determinants (BLEND) study: design and baseline characteristics. Arch Public Health 74:30
Clyde, Merlise A; Palmieri Weber, Rachel; Iversen, Edwin S et al. (2016) Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. Am J Epidemiol 184:579-589
Wilton, John; Kurenova, Elena; Pitzonka, Laura et al. (2016) Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. Eur J Drug Metab Pharmacokinet 41:55-67
Zhao, Zhiguo; Wen, Wanqing; Michailidou, Kyriaki et al. (2016) Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control 27:679-93
Shafirstein, Gal; Battoo, Athar; Harris, Kassem et al. (2016) Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc 13:265-75
Pharoah, Paul D P; Song, Honglin; Dicks, Ed et al. (2016) PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 108:
Austin, David C; Strand, Douglas W; Love, Harold L et al. (2016) NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate 76:1004-18
Sexton, Sandra; Tulowitzki, Ryan; Jones, Craig A et al. (2016) Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model. Clin Exp Nephrol 20:162-8
Chinnam, Meenalakshmi; Wang, Xiaoling; Zhang, Xiaojing et al. (2016) Evaluating Effects of Hypomorphic Thoc1 Alleles on Embryonic Development in Rb1 Null Mice. Mol Cell Biol 36:1621-7
Klinkebiel, David; Zhang, Wa; Akers, Stacey N et al. (2016) DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Mol Cancer Res 14:787-94

Showing the most recent 10 out of 1099 publications